Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.6K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.6K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.5K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profile of Autism Spectrum Disorder in Tuberous Sclerosis Complex: Results from a Longitudinal, Prospective, Multisite Study.

Annals of neurology·2021
Same author

Enhanced prime editing systems by manipulating cellular determinants of editing outcomes.

Cell·2021
Same author

Phenotypic characterization of Cdkl5-knockdown neurons establishes elongated cilia as a functional assay for CDKL5 Deficiency Disorder.

Neuroscience research·2021
Same author

Strong evidence for genotype-phenotype correlations in Phelan-McDermid syndrome: results from the developmental synaptopathies consortium.

Human molecular genetics·2021
Same author

Correction to: Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2021
Same author

Systematic Analysis of Brain MRI Findings in Adaptor Protein Complex 4-Associated Hereditary Spastic Paraplegia.

Neurology·2021

Related Experiment Video

Updated: Apr 7, 2026

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

64.0K

Developing therapies for spinal muscular atrophy.

Mary H Wertz1, Mustafa Sahin1

  • 1The F.M. Kirby Neurobiology Center, Department of Neurology, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts.

Annals of the New York Academy of Sciences
|July 16, 2015
PubMed
Summary

Spinal muscular atrophy (SMA) is a pediatric neurodegenerative disease caused by SMN1 gene mutations. Therapies aim to restore SMN protein levels, offering hope for improved motor function and lifespan.

Keywords:
antisense oligonucleotidesclinical trialsgene therapyspinal muscular atrophy

More Related Videos

Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons
10:57

Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons

Published on: July 13, 2015

13.3K
Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

21.3K

Related Experiment Videos

Last Updated: Apr 7, 2026

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

64.0K
Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons
10:57

Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons

Published on: July 13, 2015

13.3K
Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

21.3K

Area of Science:

  • Neurology
  • Genetics
  • Molecular Biology

Background:

  • Spinal muscular atrophy (SMA) is an autosomal-recessive pediatric neurodegenerative disorder resulting from mutations in the survival motor neuron 1 (SMN1) gene.
  • This genetic defect leads to a deficiency in the full-length SMN protein, crucial for motor neuron function, RNA splicing, and nuclear processes.
  • Disease severity in SMA is influenced by the expression level of the SMN protein, with even small increases yielding significant neurological improvements.

Purpose of the Study:

  • To review recent advancements in therapeutic strategies for spinal muscular atrophy.
  • To discuss novel treatments targeting the restoration of full-length SMN protein levels.
  • To explore neuroprotective approaches and emerging therapies for SMA.

Main Methods:

  • Review of current literature on basic and clinical studies for SMA treatments.
  • Analysis of therapeutic strategies including gene therapy, antisense oligonucleotides, and small molecule modulators.
  • Evaluation of approaches aimed at increasing SMN protein expression.

Main Results:

  • Significant progress has been made in developing therapeutics for SMA over the past decade.
  • Gene therapy, antisense oligonucleotides, and small molecule modulators show promise in restoring SMN protein levels.
  • These novel treatments aim to improve motor phenotypes and extend lifespan in SMA patients.

Conclusions:

  • Current interventions for SMA are largely palliative, highlighting the need for disease-modifying therapies.
  • Restoration of full-length SMN protein is a primary goal for effective SMA treatment.
  • Emerging therapeutic strategies offer potential for significant improvements in SMA patient outcomes.